Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd
SSE:600332

Watchlist Manager
Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd Logo
Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd
SSE:600332
Watchlist
Price: 28.06 CNY -3.37% Market Closed
Market Cap: 45.1B CNY
Have any thoughts about
Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd?
Write Note

Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd
Net Issuance of Debt

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd
Net Issuance of Debt Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Issuance of Debt CAGR 3Y CAGR 5Y CAGR 10Y
Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd
SSE:600332
Net Issuance of Debt
ÂĄ431.5m
CAGR 3-Years
-41%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Net Issuance of Debt
-ÂĄ19m
CAGR 3-Years
-36%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Net Issuance of Debt
ÂĄ163.2m
CAGR 3-Years
176%
CAGR 5-Years
5%
CAGR 10-Years
N/A
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Net Issuance of Debt
-ÂĄ16.1m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Yunnan Baiyao Group Co Ltd
SZSE:000538
Net Issuance of Debt
ÂĄ894.5m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Net Issuance of Debt
ÂĄ208m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd
Glance View

Market Cap
45.6B CNY
Industry
Pharmaceuticals

Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd, a leading player in China's pharmaceutical industry, stands out for its robust portfolio of products and a commitment to innovation. Founded in 1997 and headquartered in the bustling city of Guangzhou, the company has carved out a significant market presence through its diverse offerings, which include traditional Chinese medicines, chemical pharmaceuticals, and healthcare products. With a strong focus on research and development, Baiyunshan invests heavily in modernizing its production processes and expanding its product lineup, positioning itself well to capitalize on the growing demand for healthcare solutions in China and beyond. Its strategic partnerships and distribution capabilities further enhance its competitive edge, making it not just a manufacturer, but a trusted provider within the healthcare ecosystem. Investors looking at Guangzhou Baiyunshan should note the company’s impressive financial trajectory, characterized by consistent revenue growth and healthy profit margins. The pharmaceutical sector in China is poised for expansion due to an aging population and increasing health awareness, factors that bode well for Baiyunshan's future. The firm’s proactive approach to regulatory compliance and quality assurance has earned it a solid reputation with both consumers and industry stakeholders. As the company continues to enhance its research capabilities and expand its market reach, it represents a compelling opportunity for investors seeking exposure to the burgeoning Chinese pharmaceutical market. With a seasoned management team at the helm and a clear growth strategy, Guangzhou Baiyunshan is not just navigating the complexities of the pharmaceutical landscape; it is poised to thrive within it.

Intrinsic Value
36.42 CNY
Undervaluation 23%
Intrinsic Value
Price

See Also

What is Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd's Net Issuance of Debt?
Net Issuance of Debt
431.5m CNY

Based on the financial report for Jun 30, 2024, Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd's Net Issuance of Debt amounts to 431.5m CNY.

What is Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd's Net Issuance of Debt growth rate?
Net Issuance of Debt CAGR 3Y
-41%

Over the last year, the Net Issuance of Debt growth was -78%. The average annual Net Issuance of Debt growth rates for Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd have been -41% over the past three years .

Back to Top